The Latin America, Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market is expected to witness market growth of 9.4% CAGR during the forecast period (2021-2027).
In benign prostate hyperplasia therapeutics, the concept of combination therapy is rapidly becoming popular among healthcare staff and patients. A combination therapy is the integration of two or multiple drugs that are prescribed to be consumed at the same time. In addition, the combinations of drugs that come under prostate enlargement therapeutics are designed in alignment of the requirements of particular patients. This is why combination drugs are also called personalized medicines.
Moreover, the most common treatment that is widely being utilized in benign prostate hyperplasia therapeutics is the trans-urethral resection of the prostate, or also called TURP. TURP is a therapy, in which a rigid instrument is inserted in the urethra of the patient in order to diagnose the prostate enlargement. The patient is usually given anesthesia before the procedure. Moreover, transurethral resection of the prostate is a minimally invasive surgery allows no cuts on the patients’ prostate.
LAMEA is a pool of opportunities for the therapeutics industry of benign prostatic hyperplasia. Countries like South Africa and Syria are recording a high number of health-related issues that are being caused due to the substantial presence of benign prostatic hyperplasia. These issues, when combined with weaker healthcare infrastructure and facilities of countries across the region, are subject matters that require major concern.
The Brazil market dominated the LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $125 million by 2027. The Argentina market is anticipated to grow a CAGR of 10% during (2021 - 2027). Additionally, The UAE market is expected to exhibit a CAGR of 9.1% during (2021 - 2027).
Based on Therapy, the market is segmented into Mono Drug Therapy and Combination Drug Therapy. Based on Therapeutics Class, the market is segmented into Alpha Blockers, 5- alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.
By Therapy
By Therapeutics Class
By Country: Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
In benign prostate hyperplasia therapeutics, the concept of combination therapy is rapidly becoming popular among healthcare staff and patients. A combination therapy is the integration of two or multiple drugs that are prescribed to be consumed at the same time. In addition, the combinations of drugs that come under prostate enlargement therapeutics are designed in alignment of the requirements of particular patients. This is why combination drugs are also called personalized medicines.
Moreover, the most common treatment that is widely being utilized in benign prostate hyperplasia therapeutics is the trans-urethral resection of the prostate, or also called TURP. TURP is a therapy, in which a rigid instrument is inserted in the urethra of the patient in order to diagnose the prostate enlargement. The patient is usually given anesthesia before the procedure. Moreover, transurethral resection of the prostate is a minimally invasive surgery allows no cuts on the patients’ prostate.
LAMEA is a pool of opportunities for the therapeutics industry of benign prostatic hyperplasia. Countries like South Africa and Syria are recording a high number of health-related issues that are being caused due to the substantial presence of benign prostatic hyperplasia. These issues, when combined with weaker healthcare infrastructure and facilities of countries across the region, are subject matters that require major concern.
The Brazil market dominated the LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $125 million by 2027. The Argentina market is anticipated to grow a CAGR of 10% during (2021 - 2027). Additionally, The UAE market is expected to exhibit a CAGR of 9.1% during (2021 - 2027).
Based on Therapy, the market is segmented into Mono Drug Therapy and Combination Drug Therapy. Based on Therapeutics Class, the market is segmented into Alpha Blockers, 5- alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Mono Drug Therapy
- Combination Drug Therapy
By Therapeutics Class
- Alpha Blockers
- 5- alpha Reductase Inhibitors
- Phosphodiesterase-5 Inhibitors
- Others
By Country: Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Key Market Players
List of Companies Profiled in the Report:
- GlaxoSmithKline PLC (GSK)
- Astellas Pharma, Inc.
- Eli Lilly and Company
- Allergan PLC (AbbVie)
- Merck Group (Merck Sharp & Dohme Corp.)
- Boehringer Ingelheim International GmbH
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Pfizer, Inc.
- Abbott Laboratories
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapy
Chapter 4. LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
Chapter 5. LAMEA Benign Prostatic Hyperplasia Therapeutics Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Astellas Pharma, Inc.
- Eli Lilly and Company
- Allergan PLC (AbbVie)
- Merck Group (Merck Sharp & Dohme Corp.)
- Boehringer Ingelheim International GmbH
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Pfizer, Inc.
- Abbott Laboratories
Methodology
LOADING...
